TY - JOUR
T1 - Frontal EEG predictors of treatment outcome in major depressive disorder
AU - Iosifescu, Dan V.
AU - Greenwald, Scott
AU - Devlin, Philip
AU - Mischoulon, David
AU - Denninger, John W.
AU - Alpert, Jonathan E.
AU - Fava, Maurizio
N1 - Funding Information:
This study was supported by a grant from Aspect Medical Systems. Aspect Medical Systems had no further role in the study design or data collection. Dr. Greenwald and Mr. Devlin who are employees of Aspect Medical Systems have contributed to the analysis of the EEG data and are authors of this manuscript.
PY - 2009/11
Y1 - 2009/11
N2 - Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6% female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9%) responded to treatment (HAM-D-17 reduction ≥ 50%). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21%) in treatment responders than in non-responders (24%). Baseline relative theta power predicted treatment response with 63% accuracy [64% sensitivity, 62% specificity, 66% area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60% accuracy [62% sensitivity, 57% specificity, 61% AUROC (p = 0.089)]. ATR predicted response with 70% accuracy [82% sensitivity, 54% specificity, 72% AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.
AB - Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6% female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9%) responded to treatment (HAM-D-17 reduction ≥ 50%). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21%) in treatment responders than in non-responders (24%). Baseline relative theta power predicted treatment response with 63% accuracy [64% sensitivity, 62% specificity, 66% area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60% accuracy [62% sensitivity, 57% specificity, 61% AUROC (p = 0.089)]. ATR predicted response with 70% accuracy [82% sensitivity, 54% specificity, 72% AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.
KW - Antidepressants
KW - Major depressive disorder
KW - Quantitative electroencephalography (QEEG)
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=70349487527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349487527&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2009.06.001
DO - 10.1016/j.euroneuro.2009.06.001
M3 - Article
C2 - 19574030
AN - SCOPUS:70349487527
SN - 0924-977X
VL - 19
SP - 772
EP - 777
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 11
ER -
